SCHEMBL26073809

SCHEMBL26073809

C=CC(=O)N1CCC(C(=O)NCC(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
HSD17B10 Q99714 1/20 0.46
EPHX2 P34913 1/20 0.42
JAK3 P52333 1/20 0.41
KDM5A P29375 1/20 0.39
CCNK O75909 2/20 0.39
CDK12 Q9NYV4 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CDK7 P50613 1/20 0.37
CCNH P51946 1/20 0.37
MNAT1 P51948 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26073804 0.92 HSD17B10 (0.48) KMT2AHSD17B10EPHX2JAK3NPSR1
SCHEMBL26075407 0.88 KMT2A (0.46) KMT2AHSD17B10EPHX2JAK3KDM5A
SCHEMBL26077171 0.84 KDM5A (0.46) KMT2AHSD17B10JAK3KDM5ACCNK
SCHEMBL26073815 0.81 MEN1 (0.55) KMT2AJAK3KDM4ESMN1; SMN2MEN1
SCHEMBL21097014 0.81 MEN1 (0.55) KMT2AJAK3KDM4ESMN1; SMN2MEN1
SCHEMBL25837407 0.79 ALDH1A1 (0.40) JAK3CCNKCDK12SMN1; SMN2TEAD1
SCHEMBL26502211 0.79 ALDH1A1 (0.40) JAK3CCNKCDK12SMN1; SMN2TEAD1
SCHEMBL13361613 0.76 HSD17B10 (0.52) KMT2AHSD17B10EPHX2NPSR1USP2
SCHEMBL1579348 0.76 HSD17B10 (0.52) KMT2AHSD17B10EPHX2KDM4ENPSR1
SCHEMBL21097015 0.75 LMNA (0.46) KMT2AJAK3CCNKCDK12SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases Isosterix, Inc. 2024-05-07 US disclosed
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases Isosterix, Inc. 2024-05-07 US disclosed
US-20230303580-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2023-09-28 US disclosed
US-20230303580-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303580-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES KAT6A, KAT6B, KAT2A KMT2A 22/4885HSD17B10 1296/4885EPHX2 3389/4885
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases KAT6A, KAT6B, KAT2A KMT2A 22/4885HSD17B10 1296/4885EPHX2 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.